NanoViricides, Inc. (NYSEMKT:NNVC) announced on 31 march that Anil R. Diwan, Ph.D., President, Chairman, and co-Founder of the Company was recognized as the “2014 Researcher of the Year” by BusinessNewHaven, a business journal, and New Haven Magazine, publications that serve the state of Connecticut. NanoViricides Inc. (NYSEMKT:NNVC) shares after opening at $3.15 moved to $3.25 on last trade day and at the end of the day closed at $3.12. Company price to cash ratio as 9.96. NanoViricides Inc. (NYSEMKT:NNVC) showed a negative weekly performance of -15.22%.
Piper Jaffray upgraded shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from a neutral rating to an overweight rating in a research note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm currently has $84.00 price target on the stock, up from their previous price target of $75.00.
Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shares fell -4.47% in last trading session and ended the day on $69.02. PCRX return on equity ratio is recorded as -158.90% and its return on assets is -49.40%. Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) yearly performance is 151.16%.
Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) a Watertown biotech that helped ignite a wave of initial public offerings when it went public a year ago, Wednesday said it has won fast-track designation from the Food and Drug Administration to develop an antibiotic to treat urinary tract infection. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shares moved up 2.48% in last trading session and was closed at $11.58, while trading in range of $11.55 – $12.84. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) year to date (YTD) performance is -14.35%.
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, on 31 march announced full financial results for fiscal year ended December 31, 2013. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) weekly performance is 5.53%. On last trading day company shares ended up $6.49. Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) distance from 50-day simple moving average (SMA50) is 20.77%.